课题基金 / 基金详情

Fungal dysbiosis regulation of post-influenza bacterial pneumonia

Fungal dysbiosis regulation of post-influenza bacterial pneumonia
流感后细菌性肺炎的真菌失调调节
批准号:
10097806
负责人:
PETER CHEN
金额:
$59.71万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-16 至 2025-06-30

项目摘要

项目成果

PETER CHEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project summary The discovery of antibiotics in the early 20th century opened up a new era of medical treatment. Indeed, many present-day infections that are easily treated could have had deadly consequences in the absence of antibiotics. The overuse of these medicines has been a concern in the recent years due to the selection pressures that have allowed resistant bacterial species to emerge. However, another untoward consequence of antibiotics is that treatment can alter the commensal organisms of the body, which we now understand has important homeostatic functions. Indeed, many bacterial, fungal, and viral organisms that live within tissues of the body can condition the immunologic system, and an altered microbiome, such as with antibiotic use, can contribute to the development of many acute and chronic pathologies. As such, our studies demonstrate that giving prophylactic antibiotics during influenza infection (a common clinical practice) increases the risk for development of a secondary bacterial pneumonia, which is major reason for the morbidity and mortality from the initial viral illness. Although antibiotics have direct effects on decreasing the abundance and diversity of the bacterial microbiome, the newly available niche with reduced nutritional competition provides an opportunity for expansion of fungal communities. Our data demonstrates that fungal dysbiosis is a driver of worsened secondary bacteria pneumonia after influenza infection. Moreover, we find that antibiotic-induced fungal dysbiosis increases lung inflammation including augmented interferon-γ levels, a cytokine that can clear detrimental effects that contribute to post- influenza bacterial pneumonia. Finally, we find that eosinophils partially modulate the augmented lung injury, and increased gut S. cerevisiae correlates with the phenotype induced by fungal dysbiosis. Altogether, these findings support our central hypothesis that antibiotic treatment during influenza infection causes fungal dysbiosis that has lung immunomodulatory effects, which in turn increases the host susceptibility to bacterial superinfection. We will test this hypothesis in the following aims: Aim 1. Determine if fungal dysbiosis alters innate immune functions in post-influenza pneumonia. Aim 2. Evaluate how fungal dysbiosis causes lung eosinophilia to augment lung inflammation. Aim 3. Investigate the role of S. cerevisiae in mediating lung injury from post-influenza MRSA pneumonia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Syndecan-1 suppression of lung inflammation
  • 批准号:
    10463119
  • 项目类别:
  • 资助金额:
    $60.02万
  • 财政年份:
    2022
  • 负责人:
    PETER CHEN
  • 依托单位:
Syndecan-1 suppression of lung inflammation
  • 批准号:
    10613558
  • 项目类别:
  • 资助金额:
    $60.02万
  • 财政年份:
    2022
  • 负责人:
    PETER CHEN
  • 依托单位:
Syndecan-1 suppression of lung inflammation
  • 批准号:
    10792072
  • 项目类别:
  • 资助金额:
    $12.71万
  • 财政年份:
    2022
  • 负责人:
    PETER CHEN
  • 依托单位:
Fungal dysbiosis regulation of post-influenza bacterial pneumonia
  • 批准号:
    10452478
  • 项目类别:
  • 资助金额:
    $59.71万
  • 财政年份:
    2021
  • 负责人:
    PETER CHEN
  • 依托单位:
海外基金